Associated tags: HER2, Engineering, Patient, Conjugation, Drug development, Zymeworks, Biotechnology, Health, Pharmaceutical, Research, Pharmaceutical industry, Inc., Clinical Trials, Oncology, NYSE
Locations: UK, SPAIN, AUSTRALIA, WASHINGTON, NEW ZEALAND, JAPAN, CANADA, DELAWARE, IRELAND, KM, LATIN AMERICA, BRAZIL, BOSTON, BALTIMORE, MIDDLETOWN, DE, US, BRITISH COLUMBIA, NY, NEW YORK, FL, UNITED STATES
Retrieved on:
Sunday, September 4, 2022
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
Security (finance),
COVID-19,
FACP,
Breast,
CEO,
Keratitis,
Diarrhea,
Hair,
NYSE,
Safety,
Interest,
Research,
Death,
Engineering,
Paris Expo Porte de Versailles,
EST,
Chair,
Conjugation,
ESMO,
Clinical Oncology,
Interstitial lung disease,
Memorial Sloan Kettering Cancer Center,
U.S. Securities and Exchange Commission,
HER2,
Inc.,
Cancer,
Twitter,
Trae tha Truth,
CEST,
ADC,
Bispecific monoclonal antibody,
Webcast,
Private Securities Litigation Reform Act,
Drug development,
Forward-looking statement,
Patient,
Fine chemical,
Pharmaceutical industry,
Zymeworks,
MD Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the release of an abstract by ESMO with preliminary results from the companys Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the release of an abstract by ESMO with preliminary results from the companys Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific HER2 targeted antibody-drug conjugate.
- Among seven patients who experienced TRAEs of grade 3 or higher, two were grade 4 events including infusion-related reaction and decreased neutrophil count.
- There were three patient discontinuations associated with TRAEs and no reported treatment-related patient deaths or cases of interstitial lung disease.
- We are excited to share our preliminary results from the ongoing Phase 1 study at ESMO, said Kenneth Galbraith, Chair and CEO of Zymeworks.
Oncology,
Health,
Clinical Trials,
General Health,
Pharmaceutical,
Biotechnology,
U.S. Securities and Exchange Commission,
ASCO,
CEO,
Form,
SVP,
SEC,
Clinical trial,
Leadership,
Investment,
Inc.,
Security (finance),
Research,
Communication,
Annual report,
Patient,
AND,
Gynecologic cancer disparities in the United States,
NEW,
Sale,
BTC,
Breast cancer,
Safety,
Ovarian cancer,
THE,
Person,
ESMO,
ADC,
Canadian Securities Administrators,
Drug discovery,
Forward-looking statement,
HER2,
Cancer,
Engineering,
COVID-19,
Program,
Drug development,
Goal,
WHEN,
Time,
NYSE,
IND,
Workforce,
Company,
Twitter,
Therapy,
Control,
Private Securities Litigation Reform Act,
Conjugation,
Fine chemical,
Pharmaceutical industry,
Vaccine,
Tutoring,
New,
Zymeworks Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2022.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2022.
- We anticipate that this beneficial strategic move could be completed in the fourth quarter of 2022, pending necessary security holder, stock exchange, and court approvals.
- Zymeworks will present an update on its preclinical programs at an Early R&D day in New York City on October 20th, 2022.
- As of June 30, 2022, Zymeworks had $241.8 million in cash resources consisting of cash, cash equivalents and short-term investments.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Inc.,
U.S. Securities and Exchange Commission,
Twitter,
ADC,
CEO,
NYSE,
HER2,
Research,
Bispecific monoclonal antibody,
Forward-looking statement,
Paris Expo Porte de Versailles,
Private Securities Litigation Reform Act,
COVID-19,
Safety,
Conjugation,
European Society for Medical Oncology,
Drug development,
Security (finance),
Patient,
Memorial Sloan Kettering Cancer Center,
ESMO,
Engineering,
CEST,
Oncology,
Chair,
Pharmaceutical industry,
Zymeworks This presentation represents an important milestone for Zymeworks as the first opportunity to share clinical data from our zanidatamab zovodotin development program, said Kenneth Galbraith, Chair and CEO of Zymeworks.
Key Points:
- This presentation represents an important milestone for Zymeworks as the first opportunity to share clinical data from our zanidatamab zovodotin development program, said Kenneth Galbraith, Chair and CEO of Zymeworks.
- Zymeworks will host a conference call to further discuss the clinical data presented at ESMO and provide an overview on future clinical development plans for zanidatamab zovodotin after the presentation.
- Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics.
- Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Clinical Trials,
Inc.,
Twitter,
NYSE,
HER2,
Option,
Conjugation,
Drug development,
Patient,
Engineering,
Employment,
Zymeworks,
Security (finance),
Fine chemical Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the NYSE Rule), an equity inducement award to Dr. Paul Moore, Zymeworks new Chief Scientific Officer.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the NYSE Rule), an equity inducement award to Dr. Paul Moore, Zymeworks new Chief Scientific Officer.
- In accordance with the NYSE Rule, Zymeworks approved the grant of the following equity award to Dr. Moore as a material inducement to Dr. Moore entering into employment with Zymeworks: effective as of the date his employment with Zymeworks began, a stock option to purchase 200,000 of the companys common shares (the Options).
- Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
- Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas.
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Inc.,
NYSE,
Conjugation,
HER2,
Engineering,
Drug development,
Twitter,
Patient,
Fine chemical Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results after market close on August 4th, 2022.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results after market close on August 4th, 2022.
- Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 4th, 2022 at 4:30 p.m.
- Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates.
- Zymeworks second clinical candidate, ZW49, is a novel bispecific HER2 targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks proprietary ZymeLink linker and cytotoxin.
Health,
General Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
U.S. Securities and Exchange Commission,
Person,
Communication,
Time,
Chair,
D,
SEDAR,
Securities Act of 1933,
Company,
Research,
SEC,
CEO,
Tax inversion,
Securities Exchange Act of 1934,
Forward-looking statement,
Inc.,
Conjugation,
Legislation,
S&P,
Laboratory,
AND,
Patient,
Canadian Securities Administrators,
Twitter,
Supreme court,
EDGAR,
COVID-19,
Growth,
Intention,
Interest,
Proxy,
HER2,
Engineering,
NYSE,
Drug development,
Form,
NEW,
Sale,
Russell,
Law of the United Kingdom,
Annual report,
Compte rendu,
Risk management,
Security (finance),
New,
Zymeworks Zymeworks Inc. (Zymeworks or the Company) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced its intention to become a Delaware corporation (New Zymeworks), subject to receipt of necessary shareholder, stock exchange, and court approvals.
Key Points:
- Zymeworks Inc. (Zymeworks or the Company) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced its intention to become a Delaware corporation (New Zymeworks), subject to receipt of necessary shareholder, stock exchange, and court approvals.
- Becoming a Delaware corporation is an important part of our overall plan to reduce organizational and legal complexity and certain duplicative administrative costs.
- Zymeworks anticipates that the Redomicile will conclude in the fourth quarter of 2022, pending necessary shareholder, stock exchange, and court approval.
- In connection with the proposed Redomicile, Zymeworks will cause its subsidiary Zymeworks Delaware Inc., a Delaware corporation (New Zymeworks), to file a registration statement on Form S-4, which will include New Zymeworks prospectus as well as Zymeworks proxy statement (the Proxy Statement/Prospectus), with the SEC and the appropriate Canadian securities regulatory authorities.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer.
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific Officer, reporting directly to the Chief Executive Officer.
- Dr. Moore brings more than 25 years of US-based experience in biologics drug discovery and development in biotechnology research.
- I am very pleased to join Zymeworks and help in translating the transformative impact of our novel approach to antibody engineering to improve cancer treatment, said Dr. Moore.
- Dr. Moore worked on scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs.
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
One Piece,
Rights,
Conjugation,
Shareholder rights plan,
Professional corporation,
HER2,
Blake, Cassels & Graydon,
Patient,
All,
Acquisition,
NYSE,
Twitter,
Board of directors,
Board,
Inc.,
Drug development,
Engineering,
Wilson Sonsini Goodrich & Rosati,
LLP,
SEDAR,
Risk management,
Security (finance),
Zymeworks Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the Board) has adopted a limited-duration shareholder rights plan (the Rights Plan).
Key Points:
- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the Board) has adopted a limited-duration shareholder rights plan (the Rights Plan).
- The Rights Plan is intended to enable all shareholders to realize the full value of their investment in Zymeworks.
- The Rights Plan will reduce the likelihood that any entity, person or group gains control of Zymeworks through open market accumulation without paying all shareholders an appropriate control premium.
- Based on information available to Zymeworks, less than 10% of its outstanding common shares are held by shareholders in Canada.
The data are being presented in two separate poster sessions at the American Society of Clinical Oncology (ASCO) Annual Meeting June 3-7, 2022 in Chicago, IL.
Key Points:
- The data are being presented in two separate poster sessions at the American Society of Clinical Oncology (ASCO) Annual Meeting June 3-7, 2022 in Chicago, IL.
- In 33 response-evaluable patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma treated with zanidatamab and tislelizumab in combination with the CAPOX chemotherapy regimen the cORR was 75.8% (25/33).
- The most common grade 3 TRAE was diarrhea, which was manageable in the outpatient setting; introduction of prophylactic loperamide reduced the incidence from 33% to 21%.
- Though HER2-targeted agents have improved outcomes in HER2-positive breast cancer, most patients treated for advanced disease eventually relapse and develop resistant disease8,9.
Oncology,
Health,
Clinical Trials,
General Health,
Pharmaceutical,
Biotechnology,
Engineering,
Company,
HER2,
Wilson Sonsini Goodrich & Rosati,
U.S. Securities and Exchange Commission,
Chair,
Director,
Patient,
News,
COVID-19,
Inc.,
Completeness,
Research,
Scooby-Doo! Mask of the Blue Falcon,
Workforce,
LLP,
IND,
Forward-looking statement,
Board,
Safety,
Board of directors,
Drug development,
Conjugation,
Security (finance),
Blake, Cassels & Graydon,
Private Securities Litigation Reform Act,
Twitter,
One Piece,
NYSE,
Letter,
CEO,
Fine chemical,
Renewable energy,
Pharmaceutical industry,
Medical imaging,
Zymeworks Following a comprehensive review of the unsolicited, opportunistic, non-binding proposal, including independent analyses completed by external financial advisors engaged by Zymeworks, the Board of Directors has determined that the proposal significantly undervalues its prospects related to the Companys long-term business strategy and potential commercial opportunities.
Key Points:
- Following a comprehensive review of the unsolicited, opportunistic, non-binding proposal, including independent analyses completed by external financial advisors engaged by Zymeworks, the Board of Directors has determined that the proposal significantly undervalues its prospects related to the Companys long-term business strategy and potential commercial opportunities.
- As a result, the Board of Directors of Zymeworks has determined that it would not be appropriate to enter into discussions in response to the current proposal at a price of $10.50 per share.
- Lota Zoth, Zymeworks Lead Independent Director, commented, We welcome constructive engagement with, and input from, all of our shareholders.
- On April 28, 2022, the Company received an unsolicited, non-binding proposal from All Blue, which revealed its 5.9% stake in Zymeworks.
